Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022

伊朗某三级医院垂体肿瘤登记初步结果评估:2009-2022年

阅读:2

Abstract

OBJECTIVES: The Pituitary Tumor Registry intends to provide a platform for clinical research and basic sciences, with an emphasis on disease outcomes. METHODS: In this retrospective cohort study, all patient data, including demographics, vital signs, symptoms and signs, medical history, medications, past drug history, paraclinical data, treatment modalities, post-surgery follow-up, treatment responsiveness, and pathology reports, have been gathered from the electronic patient records of the Endocrinology and Metabolism Research Center affiliated with Tehran University of Medical Sciences. RESULTS: A total of 200 patients with pituitary adenoma were identified. Acromegaly was the most prevalent adenoma, accounting for 35% (n = 70) of cases, followed by clinically nonfunctional pituitary adenoma (CNFPA) at 28.5% (n = 57), prolactinoma at 23% (n = 46), and Cushing disease at 13.5% (n = 27). All of the patients with Cushing disease had surgery, with trans-sphenoidal surgery accounting for 92.59%. Prolactinoma was mostly treated with medication (82.60% of cases). Post-operative complications were reported, including cerebrospinal fluid (CSF) leakage in CNFPA cases (24.13%, n = 7) and diabetes insipidus (DI) in acromegaly (13.46%, n = 7). Unfortunately, 5 patients died: two with acromegaly, two with CNFPA and one with Cushing disease. CONCLUSIONS: This registry permits a comprehensive management, long term follow up and treatment outcomes of patients with pituitary adenomas.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。